Literature DB >> 7471600

Effects on exercise tachycardia during forty-eight hours of a series of doses of atenolol, sotalol, and metoprolol.

D W Harron, K Balnave, C D Kinney, R Wilson, C J Russell, R G Shanks.   

Abstract

Beta adrenoceptor blockers differ mainly in their plasma elimination half-lives (t 1/2 s). It has been assumed that drugs with longer t 1/2 will have a longer duration of effect on exercise tachycardia. Several factors may influence the duration of action of beta blockers; we have investigated the contribution of plasma elimination t 1/2 and dose by comparing the effects on an exercise tachycardia in healthy subjects of placebo, 25, 50, 100, and 200 mg of atenolol and of sotalol, and 50, 100, 200, and 400 mg metoprolol. Subjects exercised before and at 2, 3, 6, 8, 24, 33, and 48 hr after oral doses of each drug. Plasma samples for measurement of drug concentration were drawn before each exercise period. Twenty-four hours after 50, 100, and 200 mg atenolol and 50, 100, 200, and 400 mg sotalol there were reductions in an exercise tachycardia; at this time reductions were greater after the larger doses. The plasma elimination t 1/2s of atenolol were between 7.2 +/0 1.0 hr. Although 50, 100, and 200 mg metoprolol induced the same reductions in an exercise tachycardia 2 hr after drug as 25, 50, and 100 mg atenolol and 50, 100, and 200 mg sotalol, these doses were without effect at 24 hr. Metoprolol 400 mg reduced exercise tachycardia at 24 hr but the effect was less than that of the three largest doses of atenolol and sotalol. The plasma elimination t 1/2 for metoprolol was between 3.6 +/- 0.6 and 5.0 +/- 1.8 hr. These results show that duration of cardiac beta blocking of cardiac beta blocking activity of atenolol, sotalol, and metoprolol is determined by the elimination t 1/2 and dose.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7471600     DOI: 10.1038/clpt.1981.39

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  18 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  The beta 1- and beta 2-adrenoceptor affinity and beta 1-blocking potency of S- and R-metoprolol.

Authors:  G Wahlund; V Nerme; T Abrahamsson; P O Sjöquist
Journal:  Br J Pharmacol       Date:  1990-03       Impact factor: 8.739

3.  Chronotropic incompetence, echocardiographic abnormalities and exercise intolerance in renal transplant recipients.

Authors:  Maggie Kam Man Ma; Ming Lang Zuo; Desmond Yat Hin Yap; Maggie Ming Yee Mok; Lorraine Pui Yuen Kwan; Gary Chi Wang Chan; David Chung Wah Siu; Tak Mao Chan
Journal:  J Nephrol       Date:  2014-04-23       Impact factor: 3.902

4.  CNS-related subjective symptoms during treatment with beta 1-adrenoceptor antagonists (atenolol, metoprolol): two double-blind placebo controlled studies.

Authors:  E Dimenäs; C Dahlöf; B Olofsson; I Wiklund
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

5.  Influence of ranitidine on plasma metoprolol concentrations.

Authors:  D Jack; M Mitchard; R N Smith
Journal:  Br Med J (Clin Res Ed)       Date:  1983-06-25

Review 6.  Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update.

Authors:  J G Riddell; D W Harron; R G Shanks
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

7.  Comparison of the haemodynamic effects of bucindolol, propranolol and pindolol in healthy volunteers.

Authors:  P C O'Connor; M J Finch; D W Harron; P A Meredith; D G McDevitt; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

8.  Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol: a comparison with conventional tablets.

Authors:  A Sandberg; I Blomqvist; U E Jonsson; P Lundborg
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

9.  Design of a new multiple-unit controlled-release formulation of metoprolol--metoprolol CR.

Authors:  A Sandberg; G Ragnarsson; U E Jonsson; J Sjögren
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

10.  Assessment of beta-adrenoceptor selectivity of a new beta-adrenoceptor antagonist, bisoprolol, in man.

Authors:  A E Tattersfield; D J Cragg; R J Bacon
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.